Encompass Health stock sits at a point where a solid 5 year return record meets a valuation setup that screens as attractively priced, with both intrinsic value estimates using a Discounted Cash Flow (DCF) approach and market multiples pointing to the shares trading below what the cash flows may justify.

• Over the past 5 years, Encompass Health has returned 83.0%, which puts recent short term swings into the context of a stock that has already rewarded patient holders.
• Investor interest tied to its position in inpatient rehabilitation and demand for post acute care can support expectations for future cash flows. At the same time, any change in how the market views long term healthcare demand or policy could weigh on how much investors are willing to pay for those earnings.
• On Simply Wall St's broader checks, Encompass Health screens as undervalued in 5 of 6 areas, which leans toward the stock being cheap rather than fully priced.

The issue now is whether the current discount to intrinsic value offers enough margin of safety for investors considering Encompass Health at today's share price.

Is Encompass Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model used here is based on projected free cash flows to equity over two stages. For Encompass Health, the latest twelve month free cash flow is about $457.3 million, and the model assumes these cash flows continue growing rather than shrinking, which supports a higher estimate of long term value.

On this basis, the DCF model arrives at an intrinsic value of roughly $175.72 per share. Compared with the current share price, this indicates the stock appears about 37.3% undervalued. Analysts have highlighted upside potential linked to demand for inpatient rehabilitation, and market attention has increased even though the DCF work still points to the shares trading at a discount.

Overall, the DCF output suggests Encompass Health stock currently appears undervalued relative to the cash flows implied by the model.

Our Discounted Cash Flow (DCF) analysis suggests Encompass Health is undervalued by 37.3%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Does Encompass Health Look Undervalued on Earnings?

The P/E ratio suits Encompass Health because earnings are a key way investors judge the value of a mature healthcare operator. The stock trades on a P/E of about 18.5x, which is close to the peer average of 18.1x and below the broader Healthcare sector average of 24.7x, so the pricing does not look stretched compared with similar companies.

Simply Wall St's fair P/E estimate for Encompass Health is higher at 23.7x, which is several turns above the current 18.5x level and indicates a discount relative to what the model suggests could be reasonable given its profile and risks. If the market valued Encompass Health nearer that fair multiple, the implied pricing would be higher than today, even though current earnings already place it roughly in line with direct peers.

On this P/E yardstick, Encompass Health stock appears undervalued relative to the multiple suggested by the fair value model.

The Encompass Health Narrative: What Would Justify Today's Price?

For Encompass Health, Simply Wall St Narratives pick up where the valuation work stops. They spell out which assumptions about future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each narrative sets out a fair value as a thesis about Encompass Health's business that can be tracked over time, so you can see how well it holds up against new information.

Community views on Encompass Health are split between a meaningful discount and a modest premium, so it is worth seeing what each side is focusing on.

Bull case: 22% undervalued

"The surge in the 65-plus population and persistent undersupply of inpatient rehabilitation beds are driving high and still-unmet demand for Encompass Health's core services; ongoing hospital openings and bed expansions position the company to capture significant incremental patient volume, supporting higher revenue growth for years to come…"

Bear case: 11% overvalued

"Hospitals and rehabilitation providers are being evaluated not just on how many patients they treat, but on how well those patients recover and whether they avoid readmission…"

Do you think there's more to the story for Encompass Health? Head over to our Community to see what others are saying!

The Bottom Line

For Encompass Health, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple work point in the same direction, with the stock screening as undervalued rather than fully priced. The broad valuation checks also lean supportive, so the question for you is less about whether it is cheap today and more about why. The crux of the debate is whether inpatient rehabilitation demand and the company’s execution in post acute care are strong and durable enough to close that discount, or whether the market is correctly pricing in policy and reimbursement risks that could keep the valuation subdued.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.